Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro

Molecular Cancer Therapeutics
Adam SchayowitzAngela M H Brodie

Abstract

This study was carried out to determine the mechanisms associated with loss of androgen dependency and disease progression in prostate cancer. We investigated the role of the androgen receptor and its relationship to other signal transduction proteins. A hormone-refractory prostate cancer cell line [high-passage LNCaP (HP-LNCaP)] was established in vitro. Cells were treated with inhibitors of mammalian target of rapamycin and tyrosine kinase receptors. Expression of these proteins and the androgen receptor were measured by Western immunoblotting. Analysis of the model and various treatments was also assessed through proliferation assays, luciferase activation assays, binding assays, and ELISA. Our novel antiandrogen, VN/124-1, effectively inhibited proliferation of hormone-resistant prostate cancer cell lines (HP-LNCaP), which were no longer sensitive to bicalutamide and had increased expression of the androgen receptor. Treatment with everolimus or gefitinib resulted in an increase in protein expression and activation of the androgen receptor. Conversely, inhibition of the androgen receptor resulted in increased expression of IGFR1beta, pHER2, pmTOR, and pAkt. The addition of bicalutamide to everolimus or gefitinib inhibited c...Continue Reading

References

May 25, 1995·The New England Journal of Medicine·M E TaplinS P Balk
May 1, 1994·International Journal of Cancer. Journal International Du Cancer·H C WuL W Chung
Dec 1, 1993·The Journal of Steroid Biochemistry and Molecular Biology·C A BerrevoetsE Mulder
Nov 9, 2000·Lancet·F Labrie, B Candas
May 23, 2002·CA: a Cancer Journal for Clinicians·Beth A Hellerstedt, Kenneth J Pienta
May 30, 2003·Journal of Medicinal Chemistry·Omoshile O ClementVincent C O Njar
Oct 16, 2003·Biochemical and Biophysical Research Communications·Ning GaoXianglin Shi
Jan 2, 2004·Nature Medicine·Charlie D ChenCharles L Sawyers
Feb 3, 2004·Journal of Cellular Biochemistry·Mary-Ellen Taplin, Steven P Balk
Oct 8, 2004·The New England Journal of Medicine·Jose D Debes, Donald J Tindall
Feb 25, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S VignotE Raymond
Mar 25, 2005·Endocrine-related Cancer·Paramita M GhoshJeffrey I Kreisberg
Oct 6, 2005·Cancer Investigation·Javid JavidanRalph W de Vere White
Nov 17, 2005·Oncogene·Pradip K Majumder, William R Sellers
Mar 23, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kenneth J Pienta, Deborah Bradley
May 3, 2006·The Prostate·Celeste L KremerRaymond B Nagle

❮ Previous
Next ❯

Citations

Apr 1, 2011·Clinical & Experimental Metastasis·Steffen WedelRoman A Blaheta
Apr 16, 2013·Asian Journal of Andrology·Paul J Toren, Martin E Gleave
Nov 6, 2008·Nature Clinical Practice. Urology·Alison Hm ReidJohann S de Bono
Dec 17, 2011·The Journal of Biological Chemistry·Harris S SoiferCy A Stein
Jan 23, 2013·The Cancer Journal·Roberta Ferraldeschi, Johann de Bono
Nov 24, 2011·Prostate Cancer·Abhijit M Godbole, Vincent C O Njar
May 23, 2012·International Journal of Oncology·Rachel M SquillaceVictor M Rivera
Mar 24, 2011·Future Medicinal Chemistry·Tadas S Vasaitis, Vincent C O Njar
May 21, 2014·Nature Reviews. Clinical Oncology·Yien Ning Sophia WongJohann de Bono
Apr 26, 2014·Cell Death & Disease·A KondratskyiN Prevarskaya
Jan 7, 2014·Cancer Metastasis Reviews·Joaquin MateoJohann S de Bono
Oct 2, 2012·Annual Review of Medicine·R FerraldeschiJ de Bono
Sep 2, 2008·Expert Review of Anticancer Therapy·Mary-Ellen Taplin
Oct 23, 2012·The Urologic Clinics of North America·Terence W Friedlander, Charles J Ryan
Jan 16, 2015·Journal of Medicinal Chemistry·Vincent C O Njar, Angela M H Brodie
Nov 26, 2010·The Journal of Steroid Biochemistry and Molecular Biology·Tadas S VasaitisVincent C O Njar
Feb 7, 2012·International Journal of Cancer. Journal International Du Cancer·Nicole D FacompreRaghu Sinha
Oct 12, 2011·Molecular and Cellular Endocrinology·Andrew EichholzJohann S de Bono
May 22, 2013·The Journal of Steroid Biochemistry and Molecular Biology·Jorge A R SalvadorSamuel M Silvestre
Feb 14, 2012·Bioorganic & Medicinal Chemistry Letters·Gopal L KhatikVipin A Nair
Aug 29, 2012·Journal of Chemical Information and Modeling·Eleonora Gianti, Randy J Zauhar
Jan 11, 2018·The Aging Male : the Official Journal of the International Society for the Study of the Aging Male·Norelia TorrealbaMar Royuela
Jul 30, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Debashis SarkerJohann S de Bono
Nov 4, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bruce MontgomeryMary-Ellen Taplin
Mar 22, 2021·Biochimica Et Biophysica Acta. Molecular Basis of Disease·Vivek MakwanaShailendra Anoopkumar-Dukie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.